Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patients.

2.50
Hdl Handle:
http://hdl.handle.net/10541/108061
Title:
Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patients.
Authors:
Sharma, H; Thatcher, Nick; Baer, J; Zaki, A; Smith, A; McAuliffe, C A; Crowther, Derek; Owens, S; Fox, Brian W
Abstract:
The blood and urinary clearances of cis-diammine 1,1-cyclobutane dicarboxylate platinum(II) (CBDCA, JM8) were determined in four patients with malignancy. A 40 muCi iv injection of 191 Pt/193 Pt (3:1)-labelled CBDCA was followed by serial blood and urine sampling to 72 h. The blood clearance was triphasic, mean values for the fast, intermediate, and slow phases being 10.8 min, 2.5 h, and 125 h, respectively. The fraction of activity excreted in the urine within the first 6 h had a mean value of 66.7%, contrasting with 26.4% for cisplatin. There was only a small fraction of CBDCA excreted by the slow phase (1.5%) as against an average of 20% for CHIP and 27% for cisplatin. The early and rapid renal clearance of CBDCA may account for reduced nephrotoxicity.
Affiliation:
Department of Medical Biophysics, University of Manchester, Medical School, Manchester.
Citation:
Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patients. 1983, 11 (1):5-7 Cancer Chemother. Pharmacol.
Journal:
Cancer Chemotherapy and Pharmacology
Issue Date:
1983
URI:
http://hdl.handle.net/10541/108061
DOI:
10.1007/BF00257407
PubMed ID:
6349844
Type:
Article
Language:
en
ISSN:
0344-5704
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorSharma, Hen
dc.contributor.authorThatcher, Nicken
dc.contributor.authorBaer, Jen
dc.contributor.authorZaki, Aen
dc.contributor.authorSmith, Aen
dc.contributor.authorMcAuliffe, C Aen
dc.contributor.authorCrowther, Dereken
dc.contributor.authorOwens, Sen
dc.contributor.authorFox, Brian Wen
dc.date.accessioned2010-07-21T12:36:05Z-
dc.date.available2010-07-21T12:36:05Z-
dc.date.issued1983-
dc.identifier.citationBlood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patients. 1983, 11 (1):5-7 Cancer Chemother. Pharmacol.en
dc.identifier.issn0344-5704-
dc.identifier.pmid6349844-
dc.identifier.doi10.1007/BF00257407-
dc.identifier.urihttp://hdl.handle.net/10541/108061-
dc.description.abstractThe blood and urinary clearances of cis-diammine 1,1-cyclobutane dicarboxylate platinum(II) (CBDCA, JM8) were determined in four patients with malignancy. A 40 muCi iv injection of 191 Pt/193 Pt (3:1)-labelled CBDCA was followed by serial blood and urine sampling to 72 h. The blood clearance was triphasic, mean values for the fast, intermediate, and slow phases being 10.8 min, 2.5 h, and 125 h, respectively. The fraction of activity excreted in the urine within the first 6 h had a mean value of 66.7%, contrasting with 26.4% for cisplatin. There was only a small fraction of CBDCA excreted by the slow phase (1.5%) as against an average of 20% for CHIP and 27% for cisplatin. The early and rapid renal clearance of CBDCA may account for reduced nephrotoxicity.en
dc.language.isoenen
dc.subjectBronchial Canceren
dc.subject.meshAntineoplastic Agents-
dc.subject.meshBronchial Neoplasms-
dc.subject.meshCarboplatin-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshMelanoma-
dc.subject.meshMetabolic Clearance Rate-
dc.subject.meshMiddle Aged-
dc.subject.meshOrganoplatinum Compounds-
dc.titleBlood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patients.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Biophysics, University of Manchester, Medical School, Manchester.en
dc.identifier.journalCancer Chemotherapy and Pharmacologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.